News Stories
January 2021 Update
Final update
We have historically published news stories in the monthly schedule updates to inform our external stakeholders about
supply issues, discontinuation notices and information about new listings. As we transition into a New Year, we reflect on ways PHARMAC can better inform our stakeholders regarding these issues. We launched our new website in October 2020, and plan to use this as our main source of truth.
Notification of these issues and updates will now be published on our website:
pharmac.govt.nz/medicine-funding-and-supply/medicine-notices/
pharmac.govt.nz/pharmaceutical-schedule/updates/
Thank you for your ongoing support.
[Note: 'Tender News' and 'Looking Forward' will continue]
Tender News
Sole Subsidised Supply changes – effective 1 February 2021
|
Chemical Name |
Presentation; Pack size |
Sole Subsidised Supply brand (and supplier) |
|---|---|---|
|
Betamethasone dipropionate |
Crm 0.05%; 50 g OP |
Diprosone (MSD) |
|
Betamethasone dipropionate |
Oint 0.05%; 50 g OP |
Diprosone (MSD) |
|
Colecalciferol |
Cap 1.25 mg (50,000 iu); 12 cap |
Vit.D3 (Multichem) |
|
Hydroxyurea [hydroxycarbamide] |
Cap 500 mg; 100 cap |
Devatis (Deva) |
|
Levodopa with carbidopa |
Tab long-acting 200 mg with carbidopa 50 mg; 100 tab |
Sinemet CR (MSD) |
|
Miconazole nitrate |
Crm 2%; 15 g OP |
Multichem (Multichem) |
Looking Forward
This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.
Decisions for implementation 1 February 2021
- Hydroxyurea [hydroxycarbamide] cap 500 mg – addition of brand switch fee
- Possible decisions for future implementation 1 February 2021
- Febuxostat (Adenuric) tab 80 mg and 120 mg – amended Special Authority criteria
- Sirolimus (Rapamune) tab 1 mg, 2 mg and oral liq 1 mg per ml – amended Special Authority criteria
- Special Authority changes – reversing Covid-19 changes